Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJH8 | ISIN: FR001400K4B1 | Ticker-Symbol: 2E40
Frankfurt
19.04.24
21:49 Uhr
2,820 Euro
-0,045
-1,57 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHAXIAM THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
PHAXIAM THERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,6603,14019.04.

Aktuelle News zur PHAXIAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus143The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages,...
► Artikel lesen
09.04.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - March 29, 20241
05.04.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)197Lyon (France) and Cambridge (MA, US), 5 April 2024 - 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
20.03.Phaxiam Therapeutics S.A.: PHAXIAM Announces 2023 Full-Year Results and Provides Business Update123Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET Ongoing clinical efforts boding well to create a global phage-therapy leader in high-value indications First...
► Artikel lesen
11.03.Phaxiam Therapeutics Says Delisting Of ADSs From Nasdaq Effective4
11.03.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market431Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
05.03.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - February 29, 20241
01.03.PHAXIAM Therapeutics S.A. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities2
21.02.PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer2
20.02.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market504PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq...
► Artikel lesen
19.01.PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer2
18.01.Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024351Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and...
► Artikel lesen
03.01.Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - December 31, 20233
06.12.23Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital - November 30, 20234
16.11.23PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer2
14.11.23Erytech Pharma reports Q3 results5
14.11.23Phaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023683Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in...
► Artikel lesen
07.11.23Phaxiam Therapeutics S.A.: Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 20232
25.10.23PHAXIAM Therapeutics S.A. - 6-K, Report of foreign issuer1
24.10.23Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus520Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France)...
► Artikel lesen
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1